PMID- 33618591 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20220430 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 35 IP - 3 DP - 2022 Feb TI - Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry? PG - 415-422 LID - 10.1080/14767058.2021.1888913 [doi] AB - AIM: Bevacizumab may affect preterm infants' ongoing organogenesis with its antiangiogenic effects. We aimed to compare neurodevelopmental outcomes (NDO) of preterm infants treated for retinopathy of prematurity (ROP) with laser photocoagulation (LP), intravitreal bevacizumab (IVB) or both treatments, and to find out the effects of IVB on NDO. METHODS: Medical records of preterm infants with ROP treatment and evaluation for NDO were retrospectively collected between 1 January 2017 and 31 June 2019. Primary outcome was Bayley Scales of Infant and Toddler Development 3rd Edition (Bayley-III) scores including cognitive, language, and motor scores. Secondary outcomes were neurodevelopmental impairments (NDIs) classified as the presence of any of cerebral palsy (CP), sensorineural/mixed hearing loss, visual impairment, and developmental delay with any Bayley-III score <85. Severe NDI (sNDI) was defined as presence of any of CP with a Gross Motor Function Classification Scale of 3, 4, or 5, requirement for hearing aids or cochlear implants, bilateral visual impairment or severe developmental delay with any Bayley-III score <70. RESULTS: LP, IVB, and IVB + LP groups included 32, 12, and 10 patients, respectively. Patent ductus arteriosus treatment rates were as 68.7, 75, and 90% in groups, respectively (p<.05 between LP and IVB + LP groups). Grades 3 and 4 intraventricular hemorrhage (IVH) was lower in LP group than IVB group (9.4% vs. 33.4%, p<.05) while IVB + LP group had no grades 3 and 4 IVH. Other neonatal characteristics were similar (p > .05). CP was in 50%, 28%, and 0% of LP, IVB, and IVB + LP groups (p<.05). There was no difference in median Bayley-III cognitive, language, and motor scores between groups (p > .05). Moderate and severe developmental delays were similar between groups (p > .05) whereas IVB group had more moderate cognitive delay; and more severe cognitive, language, and motor delay. NDI rate was not different (59.3%, 50%, and 40% in groups, p > .05). sNDI was highest in IVB group but not statistically significant (31.2, 41.7, and 10% in groups, p > .05). Multiple logistic regression analysis showed that ROP treatment type and grades 3 and 4 IVH did not have any significant effect on NDO (p > .05). Odds of NDI was not effected by ROP treatment type (p > .05). CONCLUSIONS: Patients treated with bevacizumab should be carefully monitored for neurodevelopmental problems, although the frequency of grades 3 and 4 IVH in the bevacizumab group is thought to contribute to higher rates of sNDI and Bayley-III score <70. FAU - Celik, Pelin AU - Celik P AUID- ORCID: 0000-0002-3561-4542 AD - Department of Pediatrics, Division of Developmental and Behavioral Pediatrics, Ministry of Health Ankara City Hospital, Ankara, Turkey. FAU - Ayranci Sucakli, Iclal AU - Ayranci Sucakli I AUID- ORCID: 0000-0002-0995-2636 AD - Department of Pediatrics, Division of Developmental and Behavioral Pediatrics, Ministry of Health Ankara City Hospital, Ankara, Turkey. FAU - Kara, Caner AU - Kara C AUID- ORCID: 0000-0002-3628-547X AD - Department of Ophthalmology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. FAU - Petricli, Ikbal Seza AU - Petricli IS AUID- ORCID: 0000-0002-3545-303X AD - Department of Ophthalmology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. FAU - Kavurt, Sumru AU - Kavurt S AUID- ORCID: 0000-0003-0329-1846 AD - Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. FAU - Celik, Istemi Han AU - Celik IH AUID- ORCID: 0000-0002-2952-8154 AD - Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. FAU - Bas, Ahmet Yagmur AU - Bas AY AUID- ORCID: 0000-0002-1329-2167 AD - Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. AD - Department of Pediatrics, Division of Neonatology, Yildirim Beyazit University, Ankara, Turkey. FAU - Demirel, Nihal AU - Demirel N AUID- ORCID: 0000-0003-2044-2212 AD - Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. AD - Department of Pediatrics, Division of Neonatology, Yildirim Beyazit University, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20210222 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 RN - 0 (Angiogenesis Inhibitors) RN - 2S9ZZM9Q9V (Bevacizumab) SB - IM MH - Angiogenesis Inhibitors/adverse effects MH - Bevacizumab/adverse effects MH - Humans MH - Infant MH - Infant, Newborn MH - Infant, Premature MH - Intravitreal Injections MH - *Retinopathy of Prematurity/drug therapy MH - Retrospective Studies OTO - NOTNLM OT - Bayley-III scores OT - Retinopathy of prematurity OT - intravitreal bevacizumab OT - laser photocoagulation OT - neurodevelopmental outcome EDAT- 2021/02/24 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/02/23 05:38 PHST- 2021/02/24 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/02/23 05:38 [entrez] AID - 10.1080/14767058.2021.1888913 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2022 Feb;35(3):415-422. doi: 10.1080/14767058.2021.1888913. Epub 2021 Feb 22.